1. Living network meta-analysis evaluates 39 drug regimens for hidradenitis suppurativa.
2. Data from 25 randomized trials with 5,767 participants.
3. Primary measure: Hidradenitis Suppurativa Clinical Response (HiSCR).
4. Sonelokimab showed highest effectiveness.
5. Discontinuation due to adverse events were relatively low.
6. No significant superiority of new agents over adalimumab was noted. 
7. Small sample sizes hinder definitive outcomes.
8. Larger trials needed for conclusive efficacy and safety assessments.

Source: JAMA Dermatology